Do you want to be involved in research? 🔬 By sharing your experience, you can help researchers shape better care, support and understanding for others with type 1 diabetes (T1D). 💙 Explore UK-based research projects looking for people like you. Tap the link to find out more: bit.ly/4hHlMDT

Do you want to be involved in research? 🔬 By sharing your experience, you can help researchers shape better care, support and understanding for others with type 1 diabetes (T1D). 💙 Explore UK-based research projects looking for people like you. Find out more via the link: bit.ly/4hHlMDT #Type1Diabetes #GBDoc #Research

Today, history has been made: NICE has approved teplizumab for use on the NHS in England and Wales. Teplizumab is the first ever immunotherapy that can delay the onset of type 1 diabetes symptoms for people in the early stages of the condition. For the first time, we’re not just managing type 1 - we’re changing its course. This milestone means many things. But above all, it means time. More time to simply be a child. A reduction in emergency diagnoses and serious complications like diabetic ketoacidosis. A softer landing for individuals and families suddenly facing management of a life-long condition, and with it, renewed hope for the future. And this achievement belongs to you, our community. Breakthrough T1D funded early-stage research and the clinical trials that made teplizumab a reality. This breakthrough was made possible by your belief and support. Together, we are changing what’s possible. 💙 Read the full story here: bit.ly/4oJQzoo #GBDoc #Type1Diabetes #Teplizumab

Mehmet Cihangir Çatak, Bernice Lo @SidraMedicine, Safa Baris @marmara1883 et al. describe the first case of homozygous #CTLA4 deficiency, which drives severe early-onset #autoimmunity through profound T and B cell dysregulation. hubs.la/Q04kKb-M0 #Diagnostics #Therapeutics

Delighted to take part in a UCL Panel discussion on diabetes research to mark World Diabetes Day 2025 “Transforming Diabetes Care: UCL Research Innovations and Discoveries” ucl.ac.uk/medical-sciences/e…

After more than 30 years of research funded by Breakthrough T1D, we have arrived at a historic moment. Today, teplizumab has been licensed for use in the UK by the MHRA.🚨 This breakthrough treatment is the first of its kind to delay the onset of type 1 diabetes (T1D) in people at high risk of developing the condition. It represents a seismic shift in how we think about T1D and approach its treatment. MHRA approval is a critical milestone, and now teplizumab must go through the NICE (National Institute for Health and Care Excellence) technology appraisal process. Read the full story here 📖: bit.ly/4mkrqPc #Type1Diabetes #T1D #GBDoc [Image 1: Gradient blue and pink background with text that reads: The MHRA has approved teplizumab for use in the UK. Image 2: Text on a bright blue background that reads: The Medicines and Healthcare products Regulatory Agency (MHRA) has officially approved teplizumab, the first disease-modifying treatment for type 1 diabetes (T1D). This is a historic moment. Image 3: White text on a dark blue background reads: Teplizumab can delay the onset of T1D in people in the early stages of the condition by up to three years. Thanks to your continued support, Breakthrough T1D helped fund the early research that made this treatment possible. Image 4: Text on a light pink background reads: Before teplizumab can be made available through the NHS, it must go through a National Institute for Health and Care Excellence (NICE) appraisal. We'll keep advocating until this treatment is accessible to everyone who could benefit from it.]